Filing Details

Accession Number:
0001209191-22-062649
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-23 17:07:46
Reporting Period:
2022-12-01
Accepted Time:
2022-12-23 17:07:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1087294 Cumberland Pharmaceuticals Inc CPIX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1695580 Kenneth Krogulski 2525 West End Avenue
Suite 950
Nashville TN 37203
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-01 105 $2.33 202,010 No 4 P Direct
Common Stock Acquisiton 2022-12-02 105 $2.31 202,115 No 4 P Direct
Common Stock Acquisiton 2022-12-05 105 $2.19 202,220 No 4 P Direct
Common Stock Acquisiton 2022-12-06 105 $2.19 202,325 No 4 P Direct
Common Stock Acquisiton 2022-12-07 105 $2.18 202,430 No 4 P Direct
Common Stock Acquisiton 2022-12-08 105 $2.19 202,535 No 4 P Direct
Common Stock Acquisiton 2022-12-09 105 $2.15 202,640 No 4 P Direct
Common Stock Acquisiton 2022-12-12 105 $2.14 202,745 No 4 P Direct
Common Stock Acquisiton 2022-12-13 320 $2.18 203,065 No 4 P Direct
Common Stock Acquisiton 2022-12-14 320 $2.21 203,385 No 4 P Direct
Common Stock Acquisiton 2022-12-15 144 $2.24 203,529 No 4 P Direct
Common Stock Acquisiton 2022-12-16 246 $2.22 203,775 No 4 P Direct
Common Stock Acquisiton 2022-12-19 450 $2.21 204,225 No 4 P Direct
Common Stock Acquisiton 2022-12-20 370 $2.31 204,595 No 4 P Direct
Common Stock Acquisiton 2022-12-21 360 $2.22 204,955 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.